Below we provide you with informations regarding basis for advice to physicians/clinicians on the use of antivirals for 
patients performing with illness due to influenza virus infection such as oseltamivir and zanamivir (neuraminidase inhibitors) and M2 inhibitors (amantadine and rimantadine) which is issued by the World Health Organization.
This pharmacological guideline for pandemic H1N1 Influenza includes recommendations on the use of some other potensial pharmacological treatments in addition of both neuroaminidase inhibitors and M2 inhibitors. Also, it covers guidance on the use of the antivirals for other seasonal influenza strains and for infections due to novel influenza A virus strains and a table of recommended dosages of therapy.
The WHO Pharmacological Guideline in the Management of Pandemic (H1N1) 2009 Influenza can be download in the 91 page of pdf filetype (source: who.int).
